Patel Chirag K. 4/A
4/A · Amneal Pharmaceuticals, Inc. · Filed Mar 27, 2026
Research Summary
AI-generated summary of this filing
Amneal (AMRX) Co‑CEO Chirag Patel Receives Performance RSU Award
What Happened
Chirag K. Patel, President & Co‑CEO and a director of Amneal Pharmaceuticals (AMRX), received a grant of 544,663 performance-based restricted stock units (PSUs) on March 2, 2026. The award is reported at $0.00 (no cash paid); the filing classifies the transaction as a derivative award. The Form 4 is an amendment to the March 3, 2026 filing and corrects that 100% of the grant consists of performance‑based RSUs (not time‑based RSUs).
Key Details
- Transaction date: 2026-03-02; amended Form 4 filed 2026-03-27 (original Form 4 filed 2026-03-03).
- Grant: 544,663 performance-based restricted stock units (reported as the maximum number issuable).
- Price: $0.00 per unit (award/grant).
- Vesting mechanics: PSUs vest based on Amneal Class A share average closing price targets at the end of a three‑year performance period; payout may range from 0% to 200% of target. Any earned PSUs vest in full on Feb 28, 2029.
- Shares owned after transaction: not specified in the provided filing.
- Amendment note: This filing corrects the original Form 4 which inadvertently reported restricted stock units; the full grant is performance‑based RSUs.
Context
Performance-based RSUs are contingent awards — no shares or cash are received immediately and vesting depends on achievement of specified performance (stock price) criteria over the performance period. Such grants are common executive compensation and are different from open-market purchases or sales, so they do not directly signal an immediate insider buy or sell.
Insider Transaction Report
- Award
Performance-Based Restricted Stock Units
[F1][F2]2026-03-02+544,663→ 544,663 total→ Class A Common Stock (544,663 underlying)
Footnotes (2)
- [F1]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F2]Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.